FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1707578119> ?p ?o ?g. }

• W1707578119 endingPage "1777" @default.
• W1707578119 startingPage "1776" @default.
• W1707578119 abstract "Dear Editor, Tocilizumab is a humanized anti-interleukin-6 (IL-6) receptor antibody, which has recently been approved for the treatment of moderate to severe rheumatoid arthritis (RA). However, since then several types of tocilizumab-related rash have been reported. A 69-year-old woman who had been suffering from RA for over 15 years was referred to our department, complaining of symptomless skin eruptions on the extremities and trunk. She had been treated with tocilizumab (400 mg) infusion once a month for 7 months, and 2 days after the seventh infusion, erythema appeared on her upper extremities, which spread to the shoulders and lower extremities. On physical examination, multiple erythema with many tense vesicles and small pustules were widely recognized on the dorsal aspects of the upper and lower extremities (Fig. 1a). Laboratory examination showed normal ranges of white blood cell counts (3200/μL) and C-reactive protein (0.03 mg/dL), whereas increased levels of eosinophil ratio (12%), positive rheumatoid factor (93 IU/mL, normal < 20), and matrix metalloproteinase-3 (MMP-3; 715 ng/mL, normal 17.3–59.7). Serological examination revealed positive anti-nuclear antibody (1 : 160, homogeneous and speckled), anti-DNA antibody (8.3 IU/mL, normal < 6.0), and anti-double-stranded DNA immunoglobulin G (IgG) antibody was weakly positive (13 IU/mL). Serum titers of IgG antibodies to desmoglein-1 were 18 U/mL (normal index < 13), and those to desmoglein-3 were 27 U/mL (normal < 6), whereas anti-BP180 antibody was negative. Antibodies reactive to Fab fragments of tocilizumab were not detected. A biopsy specimen taken from a pustule showed a subcorneal neutrophilic abscess (Fig. 1b). There were liquefaction changes with exocytosis and a number of red blood cell extravasations. Infiltration of mononuclear cells and neutrophils were seen in the upper dermis (Fig. 1c). By contrast, eosinophil infiltration was not observed. Another specimen taken from a vesicle showed a subepidermal bulla containing a small number of neutrophils and lymphocytes. Direct immunofluorescence studies showed linear deposition of IgM along the basement membrane, whereas IgA, IgG and C3 were negative. Tocilizumab infusion was stopped and the patient was successfully treated with topical corticosteroid ointment within 1 month. Peripheral eosinophil counts returned to within normal ranges. In the presented case, widespread erythema and a number of vesicles and pustules were induced on the trunk and extremities after the seventh infusion of tocilizumab. The patient did not have prior symptoms of either upper respiratory tract infection or throat pain, and eosinophil ratio in peripheral blood was gradually increasing before the initial visit to our department. Discontinuance of tocilizumab and topical administration of corticosteroids rapidly improved the skin condition within 4 weeks, along with normalization of eosinophil ratio. To date, a few kinds of adverse skin reactions due to tocilizumab have been reported, including psoriasis1-3 erythroderma,4 papular eruptions5 and acute generalized exanthematous pustulosis (AGEP),6 some of which contain pustules. By contrast, although small pustular lesions were also intermingled with vesicles in our case, diffuse erythrodermic conditions were not recognized. Therefore, we did not consider our case as AGEP. A new onset of psoriasis during tocilizumab therapy is a paradoxical reaction, because IL-6 level is increased in psoriasis and tocilizumab is expected to be effective for psoriasis. Tocilizumab inhibits signaling from the IL-6/IL-6 receptor, which may induce a cytokine imbalance, possibly mediated via regulatory T cells.7 Alternatively, neutrophils are activated by tocilizumab by some mechanisms which are involved in the induction of some of the above skin rashes.1-3, 6 Further accumulation of similar cases and studies are warranted. None declared. None." @default.
• W1707578119 created "2016-06-24" @default.
• W1707578119 creator A5071205425 @default.
• W1707578119 creator A5071869091 @default.
• W1707578119 date "2015-07-28" @default.
• W1707578119 modified "2023-10-16" @default.
• W1707578119 title "Tocilizumab-induced pustular drug eruption" @default.
• W1707578119 cites W1933410688 @default.
• W1707578119 cites W1969021940 @default.
• W1707578119 cites W2014084267 @default.
• W1707578119 cites W2094664356 @default.
• W1707578119 cites W2121531751 @default.
• W1707578119 cites W2127059422 @default.
• W1707578119 doi "https://doi.org/10.1111/1756-185x.12658" @default.
• W1707578119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26218136" @default.
• W1707578119 hasPublicationYear "2015" @default.
• W1707578119 type Work @default.
• W1707578119 sameAs 1707578119 @default.
• W1707578119 citedByCount "6" @default.
• W1707578119 countsByYear W17075781192016 @default.
• W1707578119 countsByYear W17075781192018 @default.
• W1707578119 countsByYear W17075781192020 @default.
• W1707578119 countsByYear W17075781192022 @default.
• W1707578119 crossrefType "journal-article" @default.
• W1707578119 hasAuthorship W1707578119A5071205425 @default.
• W1707578119 hasAuthorship W1707578119A5071869091 @default.
• W1707578119 hasBestOaLocation W17075781191 @default.
• W1707578119 hasConcept C126322002 @default.
• W1707578119 hasConcept C159654299 @default.
• W1707578119 hasConcept C16005928 @default.
• W1707578119 hasConcept C203014093 @default.
• W1707578119 hasConcept C2776232647 @default.
• W1707578119 hasConcept C2777178219 @default.
• W1707578119 hasConcept C2777575956 @default.
• W1707578119 hasConcept C2779121184 @default.
• W1707578119 hasConcept C71924100 @default.
• W1707578119 hasConcept C90924648 @default.
• W1707578119 hasConceptScore W1707578119C126322002 @default.
• W1707578119 hasConceptScore W1707578119C159654299 @default.
• W1707578119 hasConceptScore W1707578119C16005928 @default.
• W1707578119 hasConceptScore W1707578119C203014093 @default.
• W1707578119 hasConceptScore W1707578119C2776232647 @default.
• W1707578119 hasConceptScore W1707578119C2777178219 @default.
• W1707578119 hasConceptScore W1707578119C2777575956 @default.
• W1707578119 hasConceptScore W1707578119C2779121184 @default.
• W1707578119 hasConceptScore W1707578119C71924100 @default.
• W1707578119 hasConceptScore W1707578119C90924648 @default.
• W1707578119 hasIssue "11" @default.
• W1707578119 hasLocation W17075781191 @default.
• W1707578119 hasLocation W17075781192 @default.
• W1707578119 hasOpenAccess W1707578119 @default.
• W1707578119 hasPrimaryLocation W17075781191 @default.
• W1707578119 hasRelatedWork W1523098566 @default.
• W1707578119 hasRelatedWork W1963511249 @default.
• W1707578119 hasRelatedWork W2031170496 @default.
• W1707578119 hasRelatedWork W2046399730 @default.
• W1707578119 hasRelatedWork W2123076451 @default.
• W1707578119 hasRelatedWork W2293819614 @default.
• W1707578119 hasRelatedWork W2312277275 @default.
• W1707578119 hasRelatedWork W2350091741 @default.
• W1707578119 hasRelatedWork W4210968471 @default.
• W1707578119 hasRelatedWork W4241984859 @default.
• W1707578119 hasVolume "20" @default.
• W1707578119 isParatext "false" @default.
• W1707578119 isRetracted "false" @default.
• W1707578119 magId "1707578119" @default.
• W1707578119 workType "article" @default.